Search results for "carcinogenesis"

showing 10 items of 6434 documents

Multifocal Biliary Cystadenocarcinoma of the Liver: CT and Pathological Findings

2006

Biliary cystadenocarcinoma is a rare tumor that originates from the hepatobiliary epithelium. Although this tumor can affect any portion of the biliary tree, intrahepatic location is more common. It is usually a slow growing tumor and often asymptomatic until it reaches a considerable size. The lesion is most often solitary and large when discovered; multiple lesions or metastases within the liver are very rare. A 63-year-old man was referred to our institute for weight loss, abdominal discomfort, worsening bulky symptoms in the right upper abdominal quadrant, and an increase in serum aminotransferases that had been present for several months. Spiral CT of the abdomen demonstrated two lesi…

MaleCancer ResearchPathologymedicine.medical_specialtyBiliary CystadenocarcinomaBiopsyCystadenocarcinoma030218 nuclear medicine & medical imagingLiver ct03 medical and health sciences0302 clinical medicineHumansMedicineCystadenocarcinomaTransaminasesbusiness.industryGeneral MedicineMiddle Agedmedicine.diseaseEpitheliumBiliary Tract Surgical ProceduresRare tumorBiliary Tract Neoplasmsmedicine.anatomical_structureOncologyChemotherapy Adjuvant030220 oncology & carcinogenesisLaparoscopyRadiologybusinessTomography Spiral ComputedTumori Journal
researchProduct

Histologic and Cytogenetic Patterns in Benign, Atypical, and Malignant Meningiomas

1995

Atypical meningiomas comprise an intermediate category of meningeal neoplasmas with some microscopic features of aggressivity and a capacity for recurrence. We present a clin ical, morphologic, and cytogenetic study of 15 meningiomas. Morphologic and cytogenetic analysis suggested the existence of morphologically typical meningiomas with normal karyotype or monosomy 22 and morphologically atypical meningiomas, with increasing chromosomal abnormalities (complex karyotype) between these two types. Present results suggest the existence of a third type of morphologically typical meningioma that lacks a phenotypical aggressivity but has a complex karyotype. These genotypical characteristics may…

0301 basic medicinePathologymedicine.medical_specialtyMonosomyAtypical meningiomaKaryotypeBiologymedicine.diseasenervous system diseasesPathology and Forensic MedicineMeningioma03 medical and health sciences030104 developmental biology0302 clinical medicine030220 oncology & carcinogenesisComplex Karyotypeotorhinolaryngologic diseasesmedicineSurgeryAnatomyneoplasmsInternational Journal of Surgical Pathology
researchProduct

3.3 Glucose levels in microregions of multicellular EMT6/Ro tumor spheroids

1991

Multicellular organismHistologyCell cultureClinical BiochemistryImmunologyTumor spheroidmedicineSpheroidCell BiologyBiologyCarcinogenesismedicine.disease_causeCell biologyProgress in Histochemistry and Cytochemistry
researchProduct

2021

Introduction (Neo-)adjuvant chemotherapy for breast cancer has a deleterious impact on muscle tissue resulting in reduced cardiorespiratory fitness, skeletal muscle mass and function. Physical exercise during treatment may counteract some of these negative effects. However, the effects of resistance training (RT) alone have never been explored. The present study aims to investigate if heavy-load RT during (neo-)adjuvant chemotherapy counteracts deleterious effects on skeletal muscle in women diagnosed with breast cancer. We hypothesize that (neo-)adjuvant treatment with chemotherapy will reduce muscle fiber size, impair mitochondrial function, and increase indicators of cellular stress and …

Muscle tissueOncologyChemotherapymedicine.medical_specialtybusiness.industrymedicine.medical_treatmentSkeletal musclePhysical exerciseCardiorespiratory fitnessGeneral Medicinemedicine.disease03 medical and health sciences0302 clinical medicinemedicine.anatomical_structureBreast cancer030220 oncology & carcinogenesisInternal medicineMyokinemedicine030212 general & internal medicinebusinessMastectomyMedicine
researchProduct

Remisión espontánea de verrugas recalcitrantes en niñas tras vacunación frente al virus del papiloma humano

2016

030207 dermatology & venereal diseases03 medical and health sciences0302 clinical medicinebusiness.industry030220 oncology & carcinogenesisMedicineGeneral MedicinebusinessActas Dermo-Sifiliográficas
researchProduct

Advances in Targeting Signal Transduction Pathways

2012

// James A. McCubrey 1 , Linda S. Steelman 1 , William H. Chappell 1 , Lin Sun 1,2 , Nicole M. Davis 1 , Stephen L. Abrams 1 , Richard A. Franklin 1 , Lucio Cocco 3 , Camilla Evangelisti 4 , Francesca Chiarini 4 , Alberto M. Martelli 3,4 , Massimo Libra 5 , Saverio Candido 5 , Giovanni Ligresti 5 , Grazia Malaponte 5 , Maria C. Mazzarino 5 , Paolo Fagone 5 , Marco Donia 5 , Ferdinando Nicoletti 5 , Jerry Polesel 6 , Renato Talamini 6 , Jorg Basecke 7 , Sanja Mijatovic 8 , Danijela Maksimovic-Ivanic 8 , Michele Milella 9 , Agostino Tafuri 10 , Joanna Dulinska-Litewka 11 , Piotr Laidler 11 , Antonio B. D’Assoro 12 , Lyudmyla Drobot 13 , Kazuo Umezawa 14 , Giuseppe Montalto 15 , Melchiorre Cer…

cancer stem cellsAMPKtherapy resistanceReviewsLibrary scienceAntineoplastic AgentsrafBiologyPI3Kampk03 medical and health sciences0302 clinical medicineCANCER STEM CELLSNeoplasmsAnimalsHumansUniversity medicalMolecular Targeted TherapyAkt; AMPK; Cancer stem cells; Metformin; MTOR; PI3K; Raf; Targeted therapy; Therapy resistanceTreatment resistanceProtein Kinase Inhibitors030304 developmental biology0303 health sciencesRoswell Park Cancer InstituteAktCancer stem cellAKTMTORAMP-ACTIVATED PROTEIN KINASE (AMPK)Raftargeted therapyMetformin3. Good healthGene Expression Regulation NeoplasticCell stressOncologyDrug Resistance NeoplasmDrug Designtargeted therapy; metformin; therapy resistance; pi3k; akt; ampk; cancer stem cells; raf; mtor030220 oncology & carcinogenesisMutationmTORMolecular targetsCancer researchmetforminSignal Transduction
researchProduct

Do Patients with Luminal A Breast Cancer Profit from Adjuvant Systemic Therapy? A Retrospective Multicenter Study

2016

Background Luminal A breast cancers respond well to anti-hormonal therapy (HT), are associated with a generally favorable prognosis and constitute the majority of breast cancer subtypes. HT is the mainstay of treatment of these patients, accompanied by an acceptable profile of side effects, whereas the added benefit of chemotherapy (CHT), including anthracycline and taxane-based programs, is less clear-cut and has undergone a process of critical revision. Methods In the framework of the BRENDA collective, we analyzed the benefits of CHT compared to HT in 4570 luminal A patients (pts) with primary diagnosis between 2001 and 2008. The results were adjusted by nodal status, age, tumor size and…

Oncologymedicine.medical_treatmentCancer Treatmentlcsh:MedicineBiochemistry0302 clinical medicineBreast TumorsMedicine and Health Sciences030212 general & internal medicinelcsh:ScienceAged 80 and overMultidisciplinaryPharmaceuticsHormonal TherapyEndocrine TherapyMiddle AgedSurvival RateOncologyChemotherapy Adjuvant030220 oncology & carcinogenesisFemaleAnatomyResearch Articlemedicine.drugClinical OncologyAdultmedicine.medical_specialtyAnthracyclineBreast NeoplasmsDisease-Free SurvivalLymphatic System03 medical and health sciencesBreast cancerDrug TherapyDiagnostic MedicineInternal medicineBreast CancerCancer Detection and DiagnosismedicineChemotherapyHumansddc:610Survival rateGrading (tumors)AgedRetrospective StudiesChemotherapyTaxanebusiness.industrylcsh:RCancers and NeoplasmsBiology and Life SciencesRetrospective cohort studymedicine.diseaseHormonesSurgerylcsh:QLymph NodesClinical MedicinebusinessTamoxifenPLOS ONE
researchProduct

Supplemental material for Quantitative and qualitative control of antineoplastic preparations: Gravimetry versus HPLC

2019

Supplemental Material for Quantitative and qualitative control of antineoplastic preparations: Gravimetry versus HPLC by Ana Sendra-García, M Amparo Martínez-Gómez, Asunción Albert-Marí, N Victor Jiménez-Torres and Mónica Climente-Martí in Journal of Oncology Pharmacy Practice

FOS: Clinical medicine111599 Pharmacology and Pharmaceutical Sciences not elsewhere classified111299 Oncology and Carcinogenesis not elsewhere classified
researchProduct

Polymorphisms in genes involved in T-cell co-stimulation are associated with blood pressure in women.

2019

In recent years, conclusive data have emerged on a relationship between immune system, especially the T-cell, and blood pressure (BP). The objective of the present study was to determine the association between BP and four polymorphisms in CD80, CD86, CD28 and CTLA4 genes that code for key proteins in the T-cell co-stimulation process, in a female cohort. To that end, an association study in a cohort of 934 women over 40 years old from two hospitals was done. Raw data showed a significant association between the SNP rs1129055 of CD86 gene and BP. Analyzing this association against inheritance patterns, higher SBP (p  0.000) and DBP (p = 0.005) values were observed in AA than in GG/GA genoty…

0301 basic medicineAdultT cellT-LymphocytesPhysiologychemical and pharmacologic phenomenaBlood PressureBiologyPolymorphism Single Nucleotide03 medical and health sciences0302 clinical medicineImmune systemCD28 AntigensGeneticsmedicineInheritance PatternsSNPHumansCTLA-4 AntigenGenetic Predisposition to DiseaseGeneCD86hemic and immune systemsGeneral MedicineMiddle Aged030104 developmental biologyBlood pressuremedicine.anatomical_structure030220 oncology & carcinogenesisCohortB7-1 AntigenFemaleB7-2 AntigenGene
researchProduct

Towards precision oncology for HER2 blockade in gastroesophageal adenocarcinoma

2019

Gastroesophageal adenocarcinoma (GEA) represents a very heterogeneous disease and patients in advanced stages have a very poor prognosis. Although several molecular classifications have been proposed, precision medicine for HER2-amplified GEA patients still represents a challenge. Despite improvement in clinical outcomes obtained by adding trastuzumab to first-line platinum-based chemotherapy, no other anti-HER2 agents used first-line or beyond progression have demonstrated any benefit. Several factors contribute to this failure. Among them, variable HER2 amplification assessment, tumour heterogeneity, molecular mechanisms of resistance and microenvironmental factors could limit the effecti…

0301 basic medicineOncologymedicine.medical_specialtyEsophageal NeoplasmsTumour heterogeneityReceptor ErbB-2DiseaseDrug resistanceAdenocarcinomaGastroesophageal Junction AdenocarcinomaGenetic Heterogeneity03 medical and health sciences0302 clinical medicineStomach NeoplasmsTrastuzumabInternal medicineAntineoplastic Combined Chemotherapy ProtocolsBiomarkers TumormedicineHumansPrecision Medicineskin and connective tissue diseasesGastroesophageal adenocarcinomabusiness.industryGene AmplificationHematologyPrognosisPrecision medicineProgression-Free SurvivalBlockade030104 developmental biologyOncologyDrug Resistance Neoplasm030220 oncology & carcinogenesisEsophagogastric Junctionbusinessmedicine.drugAnnals of Oncology
researchProduct